DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Combination Gel and Vascular ND in Mild to Moderate Rosacea

Information source: Wake Forest School of Medicine
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rosacea

Intervention: Azelaic acid (Drug); Nd:Yag laser (Device)

Phase: N/A

Status: Completed

Sponsored by: Wake Forest School of Medicine

Official(s) and/or principal investigator(s):
Amy McMichael, MD, Principal Investigator, Affiliation: Wake Forest School of Medicine


The purpose of this study is to compare efficacy and outcomes of treatment with azelaic acid (Finacea Gel) and Vascular ND: Yag laser therapy versus Vascular ND: Yag laser therapy alone via a split face study design in approximately ten to fifteen subjects with mild to moderate rosacea. We hypothesize that treatment of rosacea with combination azelaic acid (Finacea Gel) and Vascular ND: Yag laser therapy will lead to a greater improvement in lesion count, redness and telangiectasias compared to treatment with Vascular ND: Yag laser therapy alone.

Clinical Details

Official title: Combination Finacea Gel and Vascular Nd:Yag Laser Therapy for Mild to Moderate Rosacea

Study design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: IGA of Improvement

Detailed description: This is a single center, open-label, split-face, prospective study of ten to fifteen subjects seeking vascular laser therapy for the treatment of mild to moderate rosacea. Subjects will be screened for eligibility for vascular laser therapy outside of the confines of this protocol. Once approved for laser, subjects will be screened for study enrollment and topical treatment of their rosacea at the Screening/Baseline visit. All subjects will receive Finacea 15% gel and will be instructed to apply the study drug to one half of the face, twice daily. Drug application will be modified just prior to and after the subjects' laser treatment to reduce irritation. Subjects will undergo Vascular Nd: Yag laser therapy to involved areas over the whole face two weeks after initiating Finacea treatment. Subjects will continue to use Finacea gel to one half of the face for the duration of the study. Assessment of acneiform lesions, redness, and telangiectasias will be performed at Screening/Baseline, Week 2 (prior to laser treatment), and week 6/End of Study. Photography will be performed at Screening/Baseline and End of Study visits. Adverse events will be assessed at each visit, and a patient survey will be completed at Baseline and at Week 6/End of Study visits.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Male or female subject with mild to moderate rosacea, age 18 and over, who agrees to

participate and provide written consent.

- Have an Investigator Global Assessment of mild to moderate rosacea (IGA rating

between 2 and 5 in the Investigator Global Assessment (Appendix B) and at least a "Mild" rating on the Telangiectasia Rating Scale

- Subjects must be eligible to undergo vascular laser therapy and have been previously

approved for therapy. Exclusion Criteria:

- Initiation or change in dose within 4 weeks of baseline of systemic anti‐inflammatory

medication which may influence study outcome.

- Use of topical therapy for rosacea within 2 weeks of baseline.

- Use of systemic corticosteroids within 4 weeks of baseline.

- Use of systemic retinoids within 6 months of baseline

- Presence of a concurrent medical condition or skin condition, which is determined by

the investigator to potentially interfere with study outcomes or patient assessments.

- Amount of disease involvement that would require >60 gm of cream in a 6 week period.

- Subjects with known allergy or sensitivity to azelaic acid (Finacea®) gel or

components therein, such as propylene glycol.

- Contraindication to vascular laser therapy, such as infections.

- Female subjects who are not postmenopausal for at least 1 year, surgically sterile,

or willing to practice effective contraception during the study. Reliable methods of birth control are: abstinence (not having sex), oral contraceptives, intrauterine device (IUD), DepoProvera, tubal ligation, or vasectomy of the partner (with confirmed negative sperm counts) in a monogamous relationship (same partner). An acceptable, although less reliable, method involves the careful use of condoms and spermicidal foam or gel and/or a cervical cap or sponge. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.

Locations and Contacts

Wake Forest University Health Sciences Dept of Dermatology, Winston Salem, North Carolina 27104, United States
Additional Information

Starting date: July 2010
Last updated: May 27, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017